Algorae Pharmaceuticals Limited (ASX: 1AI)
Health Care · Biotechnology · AU
AU$0.01
-8.33% today · +37.5% 1Y
Algorae Pharmaceuticals Limited (ASX: 1AI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $15.97M and employs 48 people.
Over the last twelve months the share price has gained 37.5%, trading between 0.01 and 0.02.
Tweenvest scores Algorae Pharmaceuticals Limited across four factors: quality 28/100, value 67/100. Its strongest factor is value.
1AI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $15.97M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- -0.03
- 52-week high
- AU$0.02
- 52-week low
- AU$0.01
- Avg volume (3M)
- —
- Shares outstanding
- 2.03B
- Employees
- 48
- Next earnings
- —
About Algorae Pharmaceuticals Limited
Algorae Pharmaceuticals Limited, a company established in 1987 and based in Melbourne, Australia, focuses on pioneering pharmaceutical development. Known as Living Cell Technologies Limited until its rebranding in September 2023, the firm primarily conducts research and innovation in living cell technologies within New Zealand. Its development portfolio includes AI-116, a novel combination treatment pairing donepezil with cannabidiol, designed to address various forms of dementia, such as Alzheimer's disease. Another key candidate is AI-168, a unique blend of a cannabinoid and an existing, off-patent drug component, aimed at managing cardiovascular conditions like hypertension. Additionally, Algorae is progressing with NTCELL, an alginate-encapsulated product for the treatment of Parkinson's disease. The company is also collaborating with the University of New South Wales to create AlgaraeOS, an advanced drug discovery platform that utilizes artificial intelligence protocols and extensive data analytics to optimize drug identification and development processes.
- ISIN
- AU0000296022
- Founded
- 1987
- Listed since
- Aug 31, 2023
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.49 | -0.84% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.